HARBIN, China, March 22 /PRNewswire-Asia/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.
Since earlier SFDA approvals of these products, the Company has been testing production quality and evaluating stability of the final manufacturing process in preparation for commercial production. Commercialization preparation for these 13 products is now complete or nearly complete and the Company anticipates launching the products based on the following marketing timetable.
No. Product Name Description Expected
Marketing
Time
1 Oxymetazoline To treat acute and chronic March 2010
Hydrochloride rhinitis, sinusitis and
Nasal Drops allergic rhinitis
2 Moschus Liniment To relieve the pain from March 2010
for pain relief scathe, wound, rheumatism and
arthrosis
3 Ftibamzone To treat herpes and fungal April 2010
Liniment skin infection.
4 Tobramycin Eye To treat acute infection on April 2010
Drops eyelids
5 Calcium Folinate An auxiliary therapy for sprue May 2010
Injection (a disease of the small
intestine), malnutrition,
pregnancy- or infancy-related
megaloblastic anemia, and
colonic and rectal cancer
6 Sodium To treat allergic May 2010
Cromoglicate Eye conjunctivitis
Drops
7 Aciclovir Gel To treat the skin infection June 2010
due to varicella-zoster virus
and the herpes simplex virus
8 Antiasthma cream To treat cough, asthma and June 2010
chronic bronchitis
9 Naphazoline For the sterilization and June 2010
Hydrochloride rheum prevention and for the
Chlorpheniramine treatment of rheumatic
Maleate and diseases
Benzalkonium
Bromide Spray
10 Skincare Cream To treat skin diseases such as July 2010
acne, bottle nose,
chromophytosis and vitiligo
11 Nasal Drop To treat the sniffles August 2010
12 Propylgallate for To treat cerebro-vascular August 2010
Injection infarction, angina,
hypertention and coronary
heart diseases
13 Dithranol To treat different types of September 2010
ointment psoriasis, such as plaque
psoriasis, guttate psoriasis
and hypertrophy psoriasis
"We look forward to the near-term launch of several products from our R&D pipeline and are now working on the sales forecast for these products diligently. Looking ahead, we are committed to provide more transparency to the investment community about the progress of our rich R&D pipeline. We expect to continue to diversify our rich product portfolio to strengthen the Company's competitive position and support sustainable long-term growth," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include the production timeline and its effect on the Company's operational results. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the ability to launch new products, market acceptance of new product launches, the effect of changing economic conditions in The People's Republic of China, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact:
Company Contact:
China Sky One Medical, Inc.
Mr. Stanley Hao, CFO
Tel: +86-0451- 87032617
Email: stanleyhao@cski.com.cn
Investor Relations Contact:
CCG Investor Relations
Ms. Lei Huang, Account Manager
Tel: +1-646-833-3417
Email: lei.huang@ccgir.com
Web: http://www.ccgirasia.com
Ms. Mabel Zhang, Vice President
Tel: +1-310-954-1353
Email: mabel.zhang@ccgir.com
